KZIA Stock Risk & Deep Value Analysis
Kazia Therapeutics Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KZIA Stock
We analyzed Kazia Therapeutics Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KZIA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is KZIA Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for KZIA?
- âš
Further dilutive equity raises leading to significant share price erosion
- âš
Failure to secure meaningful partnerships or non-dilutive funding
- âš
Negative or inconclusive data from ongoing exploratory studies
- âš
Cash crunch leading to operational scale-down or insolvency proceedings
- âš
Delisting from NASDAQ
Unlock KZIA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Kazia Therapeutics Ltd (KZIA) Do?
Market Cap
$13.43M
Sector
Healthcare
Industry
Biotechnology
Employees
6
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Visit Kazia Therapeutics Ltd WebsiteIs KZIA Stock Undervalued?
Unlock the full AI analysis for KZIA
Get the complete DVR score, risk analysis, and more
Does KZIA Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
Highly fragile. The value of existing IP is greatly diminished post-GBM failure, and no new, strong IP or other moat sources have emerged to establish a sustainable competitive advantage.
Moat Erosion Risks
- •Inability to find new, commercially viable indications for paxalisib
- •Failure to acquire or develop new, differentiated assets
- •Competition from better-funded companies with superior pipelines
KZIA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive KZIA Stock Higher?
Near-Term (0-6 months)
- •Corporate update regarding financing or strategic review (unlikely to be significantly positive)
- •Any initial, positive (though unlikely) data readout from investigator-initiated studies for paxalisib in new indications (e.g., DIPG, brain metastases)
Medium-Term (6-18 months)
- •Announcement of a new in-licensed asset (highly speculative)
- •Update on partnership search for paxalisib in new indications (highly speculative)
- •Further dilutive financing to extend runway
Long-Term (18+ months)
- •Positive Phase 2/3 data for paxalisib in a new indication leading to regulatory pathway (highly speculative)
- •Successful pivot into a new, viable therapeutic area through acquisition or novel development
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KZIA?
- ✓
Announcement of a major, non-dilutive partnership or licensing deal for paxalisib or a new asset
- ✓
Positive Phase 2 data from paxalisib in a new, large indication (e.g., DIPG, brain metastases)
- ✓
Acquisition of a novel, late-stage clinical asset with a clear path to market
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KZIA (Kazia Therapeutics Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
